Speech-Based Artificial Intelligence for Detection of Dementia in Danish Patients (DetectAI) (DetectAI)

April 28, 2026 updated by: Zealand University Hospital

Development of Deep Learning Models for Detection of Neurodegenerative Diseases Using Speech - a Danish Language-based Artificial Intelligence Study (DetectAI)

The goal of this observational study is to learn if an artificial intelligence (AI)-based speech analysis tool can identify which patients with memory problems need specialist evaluation at a memory clinic. The main questions it aims to answer are:

Can the AI model accurately distinguish between patients who need referral to a memory clinic (those with dementia or Mild Cognitive Impairment) and patients who don't (those with normal cognition or memory problems from other causes like depression)? Which speech patterns and cognitive test features are most useful for making this distinction?

Researchers will compare speech recordings and cognitive test results from patients diagnosed with dementia or MCI to those from patients with normal cognition or non-neurodegenerative cognitive impairment to see if the AI model can reliably predict who needs specialist dementia care.

Participants will:

Complete standard cognitive tests at the memory clinic Perform structured speech tasks while being audio-recorded Receive their usual clinical evaluation and diagnosis from memory clinic specialists

The results of this study will help develop a tool that can assist doctors in making faster, more accurate decisions about which patients need specialist dementia evaluation, potentially leading to earlier diagnosis and better patient outcomes.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Background Dementia is a growing public health challenge, and early and accurate diagnosis is essential for effective care and potential future disease-modifying treatments. Current diagnostic pathways are resource-intensive and associated with long waiting times. Speech reflects cognitive functioning, and recent international studies have shown that machine learning models can detect dementia-related patterns in speech recordings with promising accuracy. This study aims to develop a speech-based deep learning model in a Danish setting, providing a non-invasive and scalable screening tool for use in primary care.

Study Design and Sampling Methods

This is an observational, cross-sectional study. Participants are recruited using two different sampling strategies corresponding to two artificial intelligence (AI) model development tracks:

Track A (Model A) - Retrospective case-control sampling:

This track addresses a focused diagnostic task: identification of Mild Cognitive Impairment (MCI). Participants are patients with a recent diagnosis from the memory clinic at Region Zealand University Hospital (ZUH). Sampling uses convenience sampling prioritizing patients who live close to the hospital, as data collection occurs during home visits. Patients with more recent diagnoses are prioritized to minimize the risk that participants have progressed to a new disease stage since diagnosis (e.g., from MCI to dementia).

Track B (Model B) - Prospective consecutive sampling:

This track uses prospective inclusion of newly referred patients to the memory clinic without pre-selection by diagnosis, reflecting a real-world clinical screening population. All eligible, consenting patients are included consecutively at their first clinic visit, before final diagnosis is established.

Model Development Following Best Practice Guidelines The study follows TRIPOD-AI (Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis - Artificial Intelligence) and PROBAST-AI (Prediction model Risk Of Bias ASsessment Tool - Artificial Intelligence) guidelines for developing and validating clinical prediction models.

Key methodological features include:

Transparent model development: All preprocessing steps, feature extraction methods, model architectures, and hyperparameters will be documented Robust validation strategy: Data will be split into training, validation, and hold-out test sets for in-depth internal validation.

Minimizing bias: Participant selection, predictor measurement, outcome determination, and statistical analysis are designed to minimize bias according to PROBAST-AI domains Clinically relevant performance metrics: Sensitivity, specificity, area under the receiver operating characteristic curve (AUC-ROC), positive and negative predictive values, and calibration Interpretability: Feature importance analysis to understand which speech characteristics contribute to predictions

Data Collection Speech data is collected through structured tasks including picture description, verbal fluency tests, story recall, and spontaneous speech. Audio is recorded using standardized equipment with quality control checks. Clinical diagnoses are established by experienced clinicians at the memory clinic following international diagnostic criteria.

Study Type

Observational

Enrollment (Estimated)

440

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Sofie J Vængebjerg, MD
  • Phone Number: +4530294621
  • Email: sova@regsj.dk

Study Contact Backup

Study Locations

  • Denmark
    • Region Sjælland
      • Roskilde, Region Sjælland, Denmark, 4000
        • Zealand University Hospital
        • Contact:
          • Sofie J Vængebjerg, MD, PhD student
          • Phone Number: +45 30294621
          • Email: sova@regsj.dk
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

Participants are recruited from patients who are followed at- or referred to the memory clinic at Zealand University Hospital. Age and gender matched healthy controls for model A are recruited from the participants' relatives.

Description

Inclusion Criteria:

Model A (patient participants)

  • Age > 50 years
  • Fluent in Danish
  • Minimum of 7 years of schooling
  • A diagnosis of either MCI or AD, given at the SUH memory clinic within 6 months before enrollment

Model A (cognitively healthy controls)

  • Age > 50 years
  • Fluent in Danish
  • Minimum of 7 years of schooling

Model B:

  • Age > 50 years
  • Fluent in Danish
  • Minimum of 7 years of schooling

Exclusion Criteria:

Model A:

Patients:

  • Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)
  • MMSE score < 16
  • Concomitant diagnoses which are expected to influence cognitive impairment (eg. depression)
  • Patients unable to give consent
  • Patients with alcohol consumption >21 standard alcohol units per week
  • Any history of speech or language impairment predating the current condition

Cognitively healthy controls:

  • Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)
  • MMSE < 26 and ACE < 90
  • Clinical, laboratory, or neuroradiological findings that could affect cognitive functions
  • Known diseases which are expected to impair cognitive functions
  • Any history of speech or language impairment predating the current condition
  • Patients with alcohol consumption >21 standard alcohol units per week.

Model B:

  • Significantly impaired vision or hearing (to the extent that the patient cannot participate in the AI analysis)
  • MMSE score < 16
  • Patients unable to give consent
  • Patients with concomitant psychosis or severe psychiatric comorbidities other than depression
  • Any history of speech or language impairment predating the current condition

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Cognitively Healthy Control Participants for Model A
We seek to enroll 40 age-matched cognitively healthy control participants for the training of model A.
Diagnostic test: Mini-mental State Examination
Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other Names:
  • MMSE
Diagnostic test: Addenbrooke's Cognitive Examination
Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other Names:
  • ACE
Other: Speech Task - Picture Description
Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.
Other: Speech Task - Picture Recall
Participants will be asked to recall the picture shown in the previous speech task "Picture Narrative". This task will take 2 minutes. Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Diagnostic test: MRI

For healthy controls an MRI will be conducted to provide comparable imaging and as part of screening to ensure they do not meet exclusion criteria (neuroradiological findings that could affect cognitive functions).

For patient participants, imaging will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

Diagnostic test: blood sampling

Healthy control participants will undergo a standard blood test panel commonly used in dementia diagnostics. The panel includes complete blood counts, inflammatory markers, kidney- and liver function markers, thyroid-stimulating hormone (TSH), vitamine B12 and folate. These tests are performed to exclude underlying medical conditions that could mimic cognitive impairment.

For patient participants, blood sampling will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

Diagnostic test: Depression screening

Performed on healthy controls to rule out depression using either the geriatric depression scale (GDS) for patients > 65 year of age or the Major Depression Index (MDI) for patiens <65 year of age.

For patient participants, depression screening will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal.

Other: Somatic- and neurological examination

Healthy controls will undergo a standard somatic and neurological examination to exclude conditions that may affect cognition. This includes basic neurological assessment and clinical evaluation of general health status.

For patient participants, a somatic and neurological examination will be performed as part of the standard diagnostic battery and results will be obtained from the electronic journal

Other: Speech Task - Picture Narrative
The participant is asked to tell a brief story based on a culturally neutral picture. This task will take approximately 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns
Patient Participants for Model A
We seek to retrospectively enroll patients from the ZUH memory clinic with a diagnosis of either Alzheimer's Disease (AD, n=50) or MCI (n=50), made within 6 months prior to enrollment. These participants will be used for the training of model A.
Diagnostic test: Mini-mental State Examination
Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other Names:
  • MMSE
Diagnostic test: Addenbrooke's Cognitive Examination
Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other Names:
  • ACE
Other: Speech Task - Picture Description
Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.
Other: Speech Task - Picture Recall
Participants will be asked to recall the picture shown in the previous speech task "Picture Narrative". This task will take 2 minutes. Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other: Speech Task - Picture Narrative
The participant is asked to tell a brief story based on a culturally neutral picture. This task will take approximately 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns
Patient Participants for Model B
We will prospectively recruit newly referred patients for the memory clinic at ZUH. Enrollment happens at first patient visit. At this time, diagnosis is not yet known, but assumed present.
Diagnostic test: Mini-mental State Examination
Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other Names:
  • MMSE
Diagnostic test: Addenbrooke's Cognitive Examination
Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other Names:
  • ACE
Other: Speech Task - Picture Description
Participants will be asked to describe the Cookie Theft Picture from the Boston Diagnostic Aphasia Examination. The task will take 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns.
Other: Speech Task - Picture Recall
Participants will be asked to recall the picture shown in the previous speech task "Picture Narrative". This task will take 2 minutes. Participants will be recorded during the test in order til allow the AI to learn and analyze speech patterns.
Other: Speech Task - Picture Narrative
The participant is asked to tell a brief story based on a culturally neutral picture. This task will take approximately 2 minutes. Participants will be recorded during the speech task in order to allow the AI to learn and analyze the speech patterns

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Model A: Primary measure is the AUC-ROC of the model in distinguishing between MCI and AD as well as between MCI and cognitively healthy control participants.
Time Frame: At baseline (speech recording)

We will measure the AUR-ROC of AI predictions compared to clinical consensus diagnosis. Metrics will be presented including uncertainty estimates.

Model performance will be measured on an independent test-set consisting of patients from the model B training population.
At baseline (speech recording)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Accuracy for dementia vs. depression
Time Frame: At baseline (speech recording)
Measured by sensitivity, specificity, AUR-ROC of AI predictions compared to clinical consensus diagnosis, using baseline speech recordings from participants. Model performance will be measured after database lock at study completion.
At baseline (speech recording)
Sub-classification of Mild Cognitive Impairment (MCI) into progressive vs. non-progressive
Time Frame: At baseline (speech recording) and up to 12 months after enrollment (to determine progression)

Measured by sensitivity, specificity, AUR-ROC of AI predictions compared to clinical consensus diagnosis, using baseline speech recordings from participants. Model performance will be measured after database lock at study completion.

Progression is defined as new dementia diagnosis during study period.
At baseline (speech recording) and up to 12 months after enrollment (to determine progression)
Classification of dementia subtypes (AD, VaD, LBD, FTD)
Time Frame: At baseline (speech recording)
Measured by sensitivity, specificity, AUR-ROC of AI predictions compared to clinical consensus diagnosis, using baseline speech recordings from participants. Model performance will be measured after database lock at study completion.
At baseline (speech recording)
Comparison with established biomarkers
Time Frame: At baseline, or at time of biomarker testing if performed after baseline
Differences in diagnostic accuracy between AI predictions and state-of-the-art biomarkers for dementia diagnosis
At baseline, or at time of biomarker testing if performed after baseline
Feature importance analysis
Time Frame: At baseline (speech recording)
Feature importance will be evaluated using interpretability analyses (e.g. permutation importance, SHAP values, and/or ablation of feature groups) to quantify the contribution of acoustic and linguistic features to the model's predictions.
At baseline (speech recording)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of tasks required for optimal accuracy
Time Frame: At baseline (speech recording)
Evaluation of whether a reduced set of speech tasks provide accuracy comparable to the full test battery.
At baseline (speech recording)
Contribution of individual speech tasks to AI model performance
Time Frame: At baseline (speech recording)
Contribution of individual speech tasks will be evaluated by comparing model performance (e.g. accuracy, sensitivity, specificity, AUC-ROC) when trained and tested on subsets of speech tasks (memory tests, story recall, picture description). This will identify which tasks provide the strongest diagnostic signal.
At baseline (speech recording)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Zealand University Hospital

Collaborators

DemensAI ApS (private tech partner, Denmark)

Investigators

  • Principal Investigator: Peter Høgh, MD, PhD, Assoc Prof, Zealand University Hospital

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

June 1, 2026

Primary Completion (Estimated)

May 1, 2028

Study Completion (Estimated)

July 1, 2028

Study Registration Dates

First Submitted

September 23, 2025

First Submitted That Met QC Criteria

September 23, 2025

First Posted (Actual)

October 1, 2025

Study Record Updates

Last Update Posted (Actual)

May 5, 2026

Last Update Submitted That Met QC Criteria

April 28, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • SJ-1107

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stress

Clinical Trials on Mini-mental State Examination

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe